Lexicon Pharmaceuticals, Inc.
LXRXHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Valued at $839.5M, LXRX is a small-cap name in its sector. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Market Cap
$839.5M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-9.16
EPS (TTM)
$-0.07
EPS (Fwd)
$-0.21
ROE
-16.0%
ROA
-5.3%
Cash
$170.7M
Total Debt
$57.7M
Free CF
-$28.9M
52W Change
186.4%
Annual Financials
Cash vs Debt
Lexicon Pharmaceuticals, Inc. holds $170.7M in cash against $57.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$28.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -16.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $139K (2022) to $49.8M (2025), reflecting a 35729% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LXRX.